New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT06873789
Summary
This early-stage study is testing a new drug called INCB177054, given alone or with an immunotherapy drug, in people with advanced solid tumors that have spread or cannot be cured by surgery. The main goals are to find a safe dose and see if the treatment can shrink tumors. It is for adults with specific cancers like head and neck, lung, or anal cancer who have few or no other treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer and Hematology Centers of Western Michigan-Start Midwest
Grand Rapids, Michigan, 49546, United States
-
Carolina Bio Oncology
Huntersville, North Carolina, 28078, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Providence Cancer Institute Franz Clinic
Portland, Oregon, 97213, United States
-
South Texas Accelerated Research Therapeutics
San Antonio, Texas, 78229, United States
-
The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
University of Florida Health Shands Hospital
Gainesville, Florida, 32610, United States
-
Upmc Cancercenter
Pittsburgh, Pennsylvania, 15232, United States
-
Valkyrie Clinical Trials
Panorama City, California, 91402, United States
Conditions
Explore the condition pages connected to this study.